Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
O'Hare T, et al. Among authors: stoffregen ep.
Blood. 2004 Oct 15;104(8):2532-9. doi: 10.1182/blood-2004-05-1851. Epub 2004 Jul 15.
Blood. 2004.
PMID: 15256422
Free article.